Until 2025, a "GLP-1 pill" meant Rybelsus — a diabetes drug at modest doses, with strict empty-stomach rules. As of 2026, two more pills carry weight-loss indications: oral Wegovy (high-dose semaglutide approved January 2025) and Foundayo (orforglipron) — the first non-peptide GLP-1 agonist, approved by FDA in April 2026 with no food or water restrictions.
Direct answer: Three GLP-1 pills are FDA approved as of May 2026: Foundayo (orforglipron) — approved April 2026, doses 1–36 mg daily, no food restriction, ~8% weight loss at 36 mg over 52 weeks in the head-to-head Lancet trial vs oral semaglutide; oral Wegovy (semaglutide) — approved January 2025, doses 1.5–25 mg daily, strict empty-stomach + 30-minute fast, 13.6% mean weight loss at 25 mg over 71 weeks; and Rybelsus (semaglutide) — approved 2019 for type 2 diabetes only, doses 3–14 mg daily, same fasting rule. Foundayo wins on convenience; oral Wegovy at top dose still produces more weight loss; injectable GLP-1s (Wegovy injection, Zepbound) remain more effective than any pill.
The Three FDA-Approved GLP-1 Pills
| Pill | Active ingredient | First approved | Indication | Available doses |
|---|---|---|---|---|
| Foundayo | Orforglipron | April 2026 | Chronic weight management | 0.8, 3, 6, 12, 24, 36 mg daily |
| Oral Wegovy | Semaglutide | January 2025 | Chronic weight management | 1.5, 4, 9, 25 mg daily |
| Rybelsus | Semaglutide | September 2019 | Type 2 diabetes | 3, 7, 14 mg daily (R1); 1.5, 4, 9 mg (R2) |
Two of the three contain the same molecule — semaglutide. Foundayo uses a different molecule (orforglipron), the first small-molecule non-peptide GLP-1 receptor agonist. Rybelsus is being repositioned with an R2 formulation expected to rebrand as "Ozempic Pill" in Q2 2026 — same drug, new packaging.
How GLP-1 Pills Work
All three drugs activate the GLP-1 receptor — the same target hit by Wegovy and Ozempic injections. Once activated, the receptor:
- Slows gastric emptying
- Increases satiety and quiets food noise
- Triggers glucose-dependent insulin release
- Suppresses glucagon
- Reduces appetite via brain receptors
The challenge for peptide GLP-1s like semaglutide is that the stomach normally destroys peptides before they reach the bloodstream. The Wegovy/Rybelsus pills solve this with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), an absorption enhancer that protects semaglutide and helps it cross the stomach lining — but only on a completely empty stomach.
Orforglipron sidesteps the problem entirely: it is not a peptide, so stomach acid doesn't destroy it. No SNAC needed, no fasting required.
Foundayo (Orforglipron) — The New One
The most consequential GLP-1 launch of 2026. Eli Lilly's small-molecule GLP-1 agonist secured FDA approval in April 2026 as the first oral GLP-1 with no food, water, or timing restrictions.
Dosing
Titration approach:
- Start at 0.8 mg daily for 4 weeks
- Step up at 4-week intervals: 3 mg → 6 mg → 12 mg → 24 mg → 36 mg target dose
- Take any time of day, with or without food, with or without water
ATTAIN-1 Trial: Obesity Data
In the ATTAIN-1 Phase 3 obesity trial of adults with overweight or obesity:
- 17.2 mg dose: ~12% mean body weight loss at ~72 weeks vs ~2% placebo
- The 36 mg dose drove larger numbers in subsets of the data
Head-to-Head vs Oral Semaglutide
The most-cited 2026 data point comes from a Lancet-published Phase 3 trial (February 26, 2026) of 1,698 adults with type 2 diabetes on metformin, randomized to orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, or oral semaglutide 14 mg for 52 weeks:
| Endpoint | Orforglipron 36 mg | Oral semaglutide 14 mg |
|---|---|---|
| A1C reduction | ~1.9–2.0 percentage points | ~1.5 percentage points |
| Weight loss | ~8.2% (~20 lb) | ~5.3% (~11 lb) |
| Treatment discontinuation for side effects | ~9.7% | ~4.9% |
Orforglipron won on both A1C and weight, but at the cost of more GI side effects and dropouts.
Side Effects and Drug Interactions
- GI symptoms (nausea, vomiting, diarrhea) dominate — comparable to injectable GLP-1s
- Treatment discontinuation due to side effects: ~9% in head-to-head trial
- Can interact with simvastatin and other drugs affected by absorption rate
- May reduce oral contraceptive effectiveness during initial treatment and dose increases — additional barrier method recommended
Mechanism
Endocrinologist Dr. Rozalina McCoy describes orforglipron as a molecule that "absorbs more readily in the gut without breaking down in the stomach." Small molecule structure (vs. peptide) is the structural difference that enables flexible dosing.
Oral Wegovy (Oral Semaglutide for Weight Loss)
Novo Nordisk's high-dose oral semaglutide, approved January 2025 specifically for chronic weight management.
Dosing
Strict titration:
- Start at 1.5 mg daily for 4 weeks
- Step up at 4-week intervals: 4 mg → 9 mg → 25 mg target
Administration rules:
- Take first thing in the morning on a completely empty stomach
- Swallow with no more than 4 oz (120 mL) of plain water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
Trial Results
OASIS-4 and related Phase 3 trials produced:
- 25 mg pill over 71 weeks: mean weight loss 13.6% (vs ~2.2% placebo)
- One trial showed 15.1% mean loss (vs 2.4% placebo)
- The matching Wegovy injection drives ~15% mean weight loss in similar trials
Side Effects
- Same GI side-effect profile as the injectable: nausea, vomiting, diarrhea, constipation
- Trial side-effect rate ~16.7% (vs 4.9% on injection comparison) — higher because of the higher daily peak concentration
- Serious risks: thyroid C-cell tumor signal (boxed warning), pancreatitis, gallbladder, kidney injury, vision changes, diabetic retinopathy
The Empty-Stomach Trap
The 30-minute fast is the real-world problem. Patients on levothyroxine, omeprazole, warfarin, or any morning medication with strict timing have to plan carefully. Mistiming weakens absorption — and missed doses can't be made up the same day.
Breastfeeding Contraindication
Animal studies showed SNAC presence in breast milk. The FDA label states: "advise patients that breastfeeding is not recommended during treatment with [oral Wegovy]." This is stricter than the injectable because of the SNAC component.
Rybelsus
The original GLP-1 pill — approved in September 2019 for type 2 diabetes only. Same molecule as oral Wegovy, but the dose range tops out at 14 mg, which is well below the 25 mg weight-loss ceiling.
Dosing
- R1 (original) formulation: 3 mg → 7 mg → 14 mg daily
- R2 (newer) formulation: 1.5, 4, 9 mg — expected to rebrand as "Ozempic Pill" in Q2 2026
- Same empty-stomach + 30-minute fast rule as oral Wegovy
Efficacy
- A1C reduction: ~1.0–1.5 percentage points at the 14 mg dose
- Weight loss: typically 4–7 lb over 6 months as a secondary effect
- Not approved for weight management — though prescribed off-label by some clinicians
Cost
- List price: $1,027.51/month
- Often well-covered by insurance for type 2 diabetes
- $25/month with the Novo Nordisk savings card for some commercially insured patients
Pill vs Injection: The Trade-Offs
| Pills | Weekly injections (Wegovy, Zepbound) | |
|---|---|---|
| Top-dose weight loss (1+ year) | ~12–14% | ~15–22% |
| Dosing frequency | Daily | Weekly |
| Needle? | No | Yes |
| Food/water rules | Strict (sema) or none (orforglipron) | None |
| Storage | Room temperature | Refrigerated until use |
| Bioavailability | ~1% (sema), higher (orforglipron) | ~80% subcutaneous |
| Out-of-pocket starting price | $149/month (Wegovy pill) | $199–$349/month |
| Manufacturer savings card | Down to $25/month for many | Down to $25/month for many |
| Missed-dose flexibility | Skip; resume next day | Take within 2 days of scheduled date |
| Travel friendliness | High | Lower (refrigeration concerns) |
Dr. Melanie Jay sums up a real benefit: "One of the benefits of the pill is that you don't have to refrigerate it and advertise you're on medication." Dr. W. Timothy Garvey adds: "It's easier to use and store the oral pill. You can travel with it and not worry about refrigeration."
The counterargument from Dr. Jay: "Patients get used to taking something once per week. I think weekly dosing leads to better adherence than daily pills."
How Effective Are the Pills, Really?
A 2025 retrospective observational study (105 adults, 2019–2022) compared GLP-1 injection users to pill users:
- Injection: 5.26 kg lost
- Pill: 3.64 kg lost
- Authors concluded the difference was "not clinically significant"
In randomized trials at top doses, the difference is larger — the injectable form has about 80% bioavailability vs ~1% for oral semaglutide, which is why pill doses are roughly 10x higher in mg terms.
Pricing (May 2026)
| Medication | List price | Self-pay starting price | With savings card |
|---|---|---|---|
| Foundayo (orforglipron) | ~$1,300/month estimated | ~$149/month starting | ~$25 with commercial insurance |
| Oral Wegovy 1.5 mg | $1,349.02 | $149/month | $25/month for many |
| Oral Wegovy 9–25 mg | $1,349.02 | $299/month | $25/month for many |
| Wegovy injection | $1,349.02 | $199 (first 2 mo), then $349 | $25/month for many |
| Rybelsus | $1,027.51 | not widely cash-priced | $25/month for many |
Medicare Part D coverage for weight-loss indications remains patchy. Diabetes use (Rybelsus, Foundayo when approved for T2D later in 2026) is reimbursed much more reliably than obesity use.
Who Can Take a GLP-1 Pill
Eligibility for oral Wegovy and Foundayo:
- BMI ≥30, OR
- BMI ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, OSA, cardiovascular disease)
Standard contraindications apply to all three:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2 (MEN2)
- Prior serious hypersensitivity to a GLP-1 receptor agonist
- Pregnancy (stop at least 2 months before trying to conceive)
- Active breastfeeding — especially relevant for oral semaglutide given SNAC
Side Effect Comparison
| Side effect | Oral semaglutide | Orforglipron | Notes |
|---|---|---|---|
| Nausea | Common, especially during titration | Common, slightly higher rates | Both fade over weeks |
| Vomiting | Common at higher doses | Slightly more frequent | Worse with high-fat meals |
| Diarrhea | Common | Common | Often resolves |
| Constipation | Common | Common | Fiber + hydration help |
| Decreased appetite | Frequent (often a goal) | Frequent | Watch protein intake |
| Headache, fatigue, dizziness | Reported | Reported | Mostly mild |
| Treatment discontinuation | ~5–7% | ~9–10% | Higher rate for orforglipron |
Both pills carry the same boxed warnings as the injectable forms (thyroid C-cell tumors, pancreatitis risk, gallbladder, vision changes).
How to Decide Between Them
| If your priority is… | Likely best pill |
|---|---|
| Maximum weight loss at any cost | Oral Wegovy 25 mg or Foundayo 36 mg |
| No food or timing restrictions | Foundayo |
| Lowest barrier to start cheap | Oral Wegovy 1.5 mg with savings card ($25/month) |
| Diabetes-first treatment | Rybelsus or (when approved for T2D) Foundayo |
| Best tolerability profile | Oral semaglutide (slightly lower discontinuation) |
| Travel-friendly, no refrigeration | Any pill — but Foundayo wins for no rules |
What People Get Wrong About GLP-1 Pills
- "The pill is the same as the shot." Same drug class, but oral semaglutide has ~1% bioavailability vs ~80% for the injection. Pill doses are roughly 10x higher in mg.
- "Rybelsus is approved for weight loss." It is not. Only oral Wegovy and Foundayo carry the weight-loss indication.
- "GLP-1 pills you can buy online without a prescription are real." Patches, drops, gummies, and "GLP-1 booster" supplements are not pharmaceutical GLP-1 agonists.
- "Side effects are milder because it's a pill." Trial data actually show higher GI side effect rates with oral semaglutide than injection because of higher peak daily concentrations.
- "Foundayo is just a stronger Wegovy." Different molecule entirely — small molecule, not a peptide. Different drug-interaction profile.
Frequently Asked Questions
What is the best GLP-1 pill for weight loss? For maximum weight loss, oral Wegovy at 25 mg (13.6%) and Foundayo at 36 mg (~12%) are the top FDA-approved options. Foundayo wins on convenience because it has no food restrictions.
How quickly does the GLP-1 pill work? Appetite and food noise typically quiet within the first 1–2 weeks. Measurable weight loss usually starts in weeks 2–4, with the biggest changes during months 3–9.
Can I take a GLP-1 pill with coffee or food? Only Foundayo. Oral Wegovy and Rybelsus require a fully empty stomach with no more than 4 oz of plain water, plus a 30-minute fast before anything else.
Is the GLP-1 pill cheaper than the injection? At the starting dose, yes — oral Wegovy is $149/month vs $199–$349/month for the injection. At the top dose, prices converge. Insurance and savings cards can drop either to $25/month.
Do GLP-1 pills cause the same side effects as Ozempic? Yes, the same profile — nausea, vomiting, diarrhea, constipation. Oral forms actually show slightly higher GI rates in some trials due to higher peak daily concentrations.
Can I buy a GLP-1 pill over the counter? No. Every FDA-approved GLP-1 pill requires a prescription. Patches, gummies, drops, and "GLP-1 booster" supplements sold OTC do not contain real GLP-1 agonists.
How long does semaglutide stay in my system after stopping the pill? Semaglutide remains active for approximately 5 weeks after the final dose. Plan for that washout if pregnancy or surgery is upcoming.
Last reviewed: May 13, 2026
Sources
- GLP-1 Weight-Loss Pills: What You Need to Know — Yale Medicine
- The New GLP-1 Pill: Everything You Need to Know in 2026 — Healthline
- Everything You Need to Know About the GLP-1 Pill — Medical News Today
- GLP-1 Pill vs Shots: What to Consider — WebMD
- Head-to-head trial shows Lilly's orforglipron outperforms oral semaglutide — Scientific American
- Lilly's GLP-1 pill tops Novo's Rybelsus in head-to-head trial — BioPharma Dive
